NasdaqGS:ONCBiotechs
BeOne Medicines Extends InSysBio Tie Up To Refine Oncology Trial Dosing
BeOne Medicines (NasdaqGS:ONC) has extended its collaboration with InSysBio to apply mechanistic translational modeling to clinical trial design.
The partnership targets better dose selection and escalation strategies, with a specific focus on reducing the risk of cytokine release syndrome in upcoming studies.
This updated agreement aims to support the company’s clinical development plans for its novel therapies.
For you as an investor watching BeOne Medicines, the key point is that this is...